Tricida, Inc. (TCDA) News
Filter TCDA News Items
TCDA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TCDA News Highlights
- 500 - Internal server error
- Over the past 23 days, the trend for TCDA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- GDRX and LAW are the most mentioned tickers in articles about TCDA.
Latest TCDA News From Around the Web
Below are the latest news stories about Tricida Inc that investors may wish to consider to help them evaluate TCDA as an investment opportunity.
Do Hedge Funds Love Tricida, Inc. (TCDA)?Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […] |
Lifshitz Law Firm, P.C. Announces Investigations of GoodRx Holdings, Inc. (NasdaqGS: GDRX), Lordstown Motors Corp. (NasdaqGS: RIDE), Tricada, Inc. (NasdaqGS: TCDA), and XL Fleet Corp. (NYSE: XL)NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- GoodRx Holdings, Inc. (NasdaqGS: GDRX) Lifshitz Law Firm, P.C. announces that a class action complaint was filed against GDRX alleging that at the time of the IPO, unbeknownst to investors, Amazon.com, Inc. was developing and would soon introduce its own online and mobile prescription medication ordering and fulfillment service that would directly compete with GDRX and that given GDRX’s knowledge of Amazon’s intention to enter the online pharmaceutical |
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Zoom, Capital One, and Tricida on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmNEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Zoom Video Communications, Inc. (NASDAQ: ZM), Capital One (NYSE: COF), and Tricida, Inc. (NASDAQ: TCDA) on behalf of long-term stockholders. More information about each potential case can be found at the link provided. Zoom Video Communications, Inc. (NASDAQ: ZM) Bragar Eagel & Squire is investigating certain officers and |
Shareholder Alert: Robbins LLP is Investigating Tricida, Inc. (TCDA) for ShareholdersShareholder rights law firm Robbins LLP is investigating Tricida, Inc. (NASDAQ: TCDA) to determine whether certain Tricida officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. Tricida is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of non-absorbed therapies. Its lead drug candidate veverimer (TRC101) is intended to slow the progression of chronic kidney disease ("CKD") th |
CORRECTING and REPLACING -- Tricida Announces First Quarter 2021 Financial ResultsWebcast Today at 4:30 pm Eastern TimeSOUTH SAN FRANCISCO, May 06, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, May 6th by Tricida, Inc. (Nasdaq: TCDA), please note that the first and second bullets of the "Upcoming Milestones" should have been combined into one bullet. The corrected release follows: Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis and slow CKD progression in patients with chronic kidney disease (CKD), announced today financial results for the three months ended March 31, 2021 and provided an update on key initiatives. Recent Events Tricida continues t... |
Tricida Announces First Quarter 2021 Financial ResultsWebcast Today at 4:30 pm Eastern TimeSOUTH SAN FRANCISCO, May 06, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis and slow CKD progression in patients with chronic kidney disease (CKD), announced today financial results for the three months ended March 31, 2021 and provided an update on key initiatives. Recent Events Tricida continues to execute on recruitment and conduct of the VALOR-CKD renal outcomes trial. As of May 4, 2021, the VALOR-CKD renal outcomes trial has randomized 1,440 of 1,600 subjects with an average treatment duration of approximately 15 months and has accrued ... |
Tricida, Inc. to Host Earnings CallNEW YORK, NY / ACCESSWIRE / May 6, 2021 / Tricida, Inc. (NASDAQ:TCDA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern Time. |
Tricida (TCDA) Sees Hammer Chart Pattern: Time to Buy?Tricida (TCDA) has been struggling lately, but the selling pressure may be coming to an end soon |
Have Insiders Been Buying Tricida, Inc. (NASDAQ:TCDA) Shares This Year?It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also... |
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of TCDA, REGI and ATNXNEW YORK, NY / ACCESSWIRE / March 8, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. |